論文

2017年8月

Optimized treatment strategy of radiotherapy for early glottic squamous cell carcinomas: An initial analysis

NAGOYA JOURNAL OF MEDICAL SCIENCE
  • Kana Kimura
  • Yoshiyuki Itoh
  • Tohru Okada
  • Seiji Kubota
  • Mariko Kawamura
  • Rie Nakahara
  • Yumi Oie
  • Yuka Kozai
  • Yuuki Takase
  • Hidenori Tsuzuki
  • Naoki Nishio
  • Mariko Hiramatsu
  • Yasushi Fujimoto
  • Takefumi Mizutani
  • Shinji Naganawa
  • 全て表示

79
3
開始ページ
331
終了ページ
338
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.18999/nagjms.79.3.331
出版者・発行元
NAGOYA UNIV, SCH MED

The purpose of this study was to evaluate the clinical outcomes of radiotherapy for patients with T1/T2 glottic carcinoma. Patients with T1/T2 glottic carcinoma histopathologically diagnosed with squamous cell carcinoma and treated at our hospital between 2007 and 2015 were analyzed retrospectively. Our strategy for T1/T2 glottic carcinoma was as follows: radiotherapy alone with 2.25 Gy per fraction to a total of 25-28 fractions for patients with non-bulky T1 glottic carcinoma; concurrent chemoradiotherapy with oral S-1 and radiotherapy with 2 Gy per fraction to a total of 30 fractions for patients with T1 bulky/T2 favorable glottic carcinoma; or chemoradiotherapy with high-dose cisplatin and radiotherapy with 2 Gy per fraction to a total of 35 fractions for T2 unfavorable glottic carcinoma. Forty-eight patients were eligible. The median follow-up period among surviving patients was 38 months (range, 11-107). The disease was T1a in 23%, T1b in 13%, and T2 in 65% of patients. The 3-year local control rate in all patients, T1a, T1b, and T2 was 96.7%, 100%, 100%, and 96.0%, respectively. Of the 46 patients, one with T2 glottic carcinoma developed recurrent disease at the primary site, and one with T2 glottic carcinoma had lymph node recurrences in the neck. Acute Grade 3 dermatitis occurred in 8 (17%) patients and late Grade 2 hypothyroidism occurred in 2 (4%) patients. This retrospective study shows that our optimized treatment strategy of radiotherapy depending on the stage of early glottic carcinoma is not only effective but also well-tolerated.

リンク情報
DOI
https://doi.org/10.18999/nagjms.79.3.331
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/28878438
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000408062800006&DestApp=WOS_CPL
ID情報
  • DOI : 10.18999/nagjms.79.3.331
  • ISSN : 2186-3326
  • eISSN : 0027-7622
  • PubMed ID : 28878438
  • Web of Science ID : WOS:000408062800006

エクスポート
BibTeX RIS